ARWR - Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)
2024-03-30 05:16:41 ET
Summary
- Arrowhead Pharmaceuticals has faced setbacks and obstacles in securing commercial approval for its drugs, leading to a decline in its stock price.
- Partnerships with Janssen and Horizon Therapeutics have been terminated, and several drug candidates have been shelved.
- Arrowhead's near-term approval shots include plozasiran, olpasiran, and fazirsiran, but they face competition from other companies in their respective markets.
Investment Overview
Back in 2019 I covered Arrowhead Pharmaceuticals ( ARWR ), a drug developer focused on RNA-interference therapeutics in a note for Seeking Alpha.
The note still provides an accurate overview of Arrowhead's history, from acquiring RNA assets and a manufacturing facility from Swiss Pharma giant Roche (OTCQX: RHHBY ), to purchasing another Swiss Pharma, Novartis' ( NVS ) RNA-interference portfolio, assets it failed to develop successfully, before two mega-deals were agreed with Californian Pharma giant Amgen ( AMGN ), and Johnson & Johnson ( JNJ ) drug development subsidiary Janssen in 2018, to co-develop a variety of pipeline assets, leading to a surge in the company's valuation....
Arrowhead: RNAi Specialist Struggling To Show A Strong Hand (Rating Downgrade)